The Institute for Clinical and Economic Review (ICER) is in its third year of reviewing fair access to prescription drugs, but continues to face obstacles to doing a thorough assessment. Greater transparency is needed to make a clearer evaluation of consumers’ access to the drugs they are prescribed, the report – which deemed only two of 18 drugs included to be fairly priced and eligible for cost-sharing analysis – concludes.
Key Takeaways
-
The Institute for Clinical and Economic Review says insurers and other payers are meeting much of its recommendations for fair access to drugs, but more information is needed for a thorough assessment.
